insights_auto
Why is ARGX down 2.17%?
Dive Deeperchevron_right
ARGX:NASDAQ
argenx SE - ADR
$960.04
arrow_downward
-2.17%(-21.29) 1D
$960.04
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARGX...
Open
$975.62
High
$976.85
Low
$959.27
Mkt. cap
60.49B
Avg. vol.
473.60K
Volume
225.89K
P/E ratio
33.18
52-wk high
$1,072.75
52-wk low
$661.85
EPS
$28.94
Beta
0.48
Shares outstanding
62.89M
No. of employees
2K
Open
$975.62
High
$976.85
Low
$959.27
Mkt. cap
60.49B
Avg. vol.
473.60K
Volume
225.89K
P/E ratio
33.18
52-wk high
$1,072.75
52-wk low
$661.85
EPS
$28.94
Beta
0.48
Shares outstanding
62.89M
No. of employees
2K
News stories
From web sources and news partners
GuruFocus
·
12 hours ago
ARGX Maintained by Morgan Stanley -- Price Target Lowered to $1130
Yahoo Finance
·
3 days ago
argenx (ENXTBR:ARGX) Stock May Look Fully Priced Despite Its $1.15B Deal
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR
CEO-
Employees1.86K
FoundedApr 25, 2008
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteargenx.com